

HIV sequence database

DATABASES SEARCH Search Site **ALIGNMENTS TOOLS PUBLICATIONS GUIDES**

51 sets found:

Retrieve selected sets

# Select	Pat code(id)		# of timepoints	First author	Publication title	Project Post or Fiebig (Organism
1 🗆	N70(45921) N58(45925) N82(45927) N35(45928) N64(45929) N72(45932)	16 11 11 11	1 1 1 1 1	Amoedo et al.	Expression of APOBEC3G/3F and G-to-A Hypermutation Levels in HIV-1-Infected Children with Different Profiles of Disease Progression	seroconversion	HIV-1
2 🗆	R880F(51709)		5	Baalwa et al.	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones	IAVI CHAVI seroconversion firstsample fiebig	HIV-1
3	P00005(11880) P00019(11892) P00020(11893) P00021(11894) P00022(11895) P00025(11898) P00028(11900) P00029(11901) P00050(11921) P00051(11922) P00053(11924) P00055(11925)	58 35 17 55 12		Bacheler et al.	Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy	DMP266	HIV-1

	<u>P00057</u> (11927)	40					
	<u>P00058</u> (11928)	27					
	<u>P00059</u> (11929)	12					
	<u>P00060</u> (11930)	48					
	<u>P00069</u> (11938)	48					
	<u>P00071</u> (11939)	36					
	<u>P00072</u> (11940)	36					
	<u>P00082</u> (11949)	20					
	<u>P00099</u> (11963)	37					
	P00123(11984)	18					
	<u>P00003</u> (15634)	33					
	<u>P00026</u> (15637)	62					
	<u>P00054</u> (15639)	13					
	<u>P00070</u> (15641)	54					
	<u>P00077</u> (15642)	51					
	<u>P00162</u> (15653)	39					
4	<u>15</u> (23708)	76	2 <u>E</u>	Balamurugan et	Primary human	seroconversion	HIV-1
	47/22700)		2	<u>al.</u>	immunodeficiency virus type		
	<u>16</u> (23709)	61	2		1 (HIV-1) infection during HIV-1 Gag vaccination		
5	<u>53431</u> (44072)	31		Bansode et al.			HIV-1
	<u>54094</u> (44074)	25		<u> </u>	drug-naive HIV type 1		,
	<u>54023</u> (44080)	27			subtype C-infected		
	<u>53394</u> (44106)	30			<u>individuals from rural</u> <u>Malawi.</u>		
	<u>53900</u> (44110)	26			matawi.		
	<u>53843</u> (44125)	32					
	<u>54117</u> (44128)	21					
	<u>53733</u> (44134)	20					
6	<u>patient A</u> (16597)	19	1	Byrn et al.	HIV-1 in semen: an isolated	seroconversion	HIV-1
	,				virus reservoir		
7	<u>24</u> (10775)	145	3	<u>Delobel et al.</u>	Persistence of distinct HIV-1	seroconversion	HIV-1
					populations in blood	starttreatment	
					monocytes and naive and memory CD4 T cells during		
					prolonged suppressive		
					HAART.		
8	<u>P1</u> (39766)	123	2	English et al.	Phylogenetic analysis	infection	HIV-1
					consistent with a clinical	seroconversion	

		<u>P2</u> (39767)	107	2		history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.		
9		<u>WC1-001</u> (3094)	10	2	Fang et al.	Analysis of transition from long-term nonprogressive to progressive infection identifies sequences that may attenuate HIV type 1	seroconversion	HIV-1
10		<u>WC1-001</u> (3094)	10	2	Fang et al.	Complete Plasma HIV-1 Sequence: Sp1-Promoter Deletion Can Lead to Non- Progressive Infection		HIV-1
11		<u>WC1-001</u> (3094)	10	2	Fang et al.	Molecular cloning of full- length HIV-1 genomes directly from plasma viral RNA.		HIV-1
12		<u>MM43</u> (39684)	75	2	<u>Ferrari et al.</u>	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection	cohort	HIV-1
13		N1(50603) N3(50605) N2(50606) N5(50609) N4(50611)	48 31 47 31 30		Fourati et al.	HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs.		HIV-1
14		<u>S1</u> (1651)	130	9	Frenkel et al.	Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy	firstsample	HIV-1
15		<u>E</u> (47532) <u>B</u> (47533)		2	Ghosn et al.	X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI		HIV-1
16	1 /	PIC38417(49597)	93	9	Herbeck et al.		UW seroconversion	HIV-1

	<u>PIC51550</u> (49598)	10	1		affect HIV-1 evolution in primary infection before the			
	PIC11286(49604)	30	3		onset of selective processes			
	PIC88403(49613)	10	1					
	PIC38051(49614)	18	2					
	PIC71101(49623)	84	8					
	PIC90770(49636)	68	7					
	PIC55751(49637)	40	5					
	PIC83747(49641)	123	12					
17	<u>PIC1362</u> (13654)	1185	17	<u>Herbeck et al.</u>	Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes	se	roconversion	HIV-1
18	<u>3</u> (815)	319	6	Imamichi et al.	Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy	sta	roconversion firstsample arttreatment ndtreatment	HIV-1
19	<u>3026</u> (10348)	10		<u>Janini et al.</u>	Human immunodeficiency virus type 1 DNA sequences	se	roconversion	HIV-1
	<u>4002</u> (10354)	17			genetically damaged by hypermutation are often			
	<u>6950</u> (10360)	12			abundant in patient			
	<u>6953</u> (10361)	12			peripheral blood mononuclear cells and may be generated during near-			
	<u>9002</u> (10365)	11			simultaneous infection and activation of CD4(+) T cells			
20	<u>6248</u> (15903)	45	2	<u>Jiang et al.</u>	Primary Infection by a Human Immunodeficiency Virus with Atypical Coreceptor Tropism.	CHAVI se	roconversion fiebig	HIV-1
21	<u>OP428</u> (19538)	154	1	<u>Karlsson et al.</u>	Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape	OPTIONS	infection	HIV-1
22	<u>CT-F</u> (79974)	159	5	<u>Kayondo et al.</u>	Intrapatient Evolutionary Dynamics of Human		firstsample	HIV-1

		<u>STI-F</u> (79975)	198	5		Immunodeficiency Virus Type 1 in Individuals Undergoing			
		<u>STI-S</u> (79976)	108	3		Alternative Treatment Strategies with Reverse Transcriptase Inhibitors.			
23		<u>1001</u> (31787)	124	2	<u>Kearney et al.</u>	Human immunodeficiency	S€	eroconversion	HIV-1
		<u>3024</u> (32691)	165	7		virus type 1 population			
		<u>1002</u> (32692)	163	8		genetics and adaptation in newly infected individuals			
		<u>1005</u> (32693)	215	8		nemy infected marriadas			
		<u>3041</u> (32694)	136	6					
		<u>1003</u> (32695)	278	6					
		<u>3088</u> (32696)	107	6					
		<u>3036</u> (32697)	86	4					
		<u>3021</u> (32698)	156	9					
		<u>1004</u> (32699)	219	11					
		<u>1006</u> (32700)	136	7					
		<u>3037</u> (32701)	127	6					
		<u>3077</u> (32702)	116	5					
		<u>3062</u> (32703)	142	5					
2.4		WC2(27470)	2.0	4.4	17 1 1	T 101 C 1 1 1 1			1.10.7.4
24	✓	<u>WC3</u> (27170)	39	11	Kemal et al.	Transition from long-term nonprogression to HIV-1 disease associated with escape from cellular immune control.	Wadsworth Center	infection	HIV-1
25		<u>WC3</u> (27170)	39 53	11		nonprogression to HIV-1 disease associated with escape from cellular immune		infection	HIV-1
	_					nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel			
	_	<u>237</u> (53226)	53	2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227)	53 66	2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel			
	_	237(53226) 276(53227) 620(53229)	53 66 56	2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230)	53 66 56 52	2 2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234)	53 66 56 52 94	2 2 2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234) 838(53235)	53 66 56 52 94 61	2 2 2 2 2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234) 838(53235) 740(53239)	53 66 56 52 94 61 40	2 2 2 2 2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234) 838(53235) 740(53239) 471(53240)	53 66 56 52 94 61 40 63	2 2 2 2 2 2 2 1 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234) 838(53235) 740(53239) 471(53240) 168(53241)	53 66 56 52 94 61 40 63 74	2 2 2 2 2 2 1 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234) 838(53235) 740(53239) 471(53240) 168(53241) 201(53242)	53 66 56 52 94 61 40 63 74 51	2 2 2 2 2 2 1 2 2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			
	_	237(53226) 276(53227) 620(53229) 046(53230) 909(53234) 838(53235) 740(53239) 471(53240) 168(53241) 201(53242) 027(53250)	53 66 56 52 94 61 40 63 74 51 75	2 2 2 2 2 1 2 2 2 2 2		nonprogression to HIV-1 disease associated with escape from cellular immune control. HIV-1 pol Diversity among Female Bar and Hotel Workers in Northern			

		<u>066</u> (53256)	45	2				
		<u>087</u> (53257)	57	2				
		<u>733</u> (53259)	135	2				
		<u>968</u> (53260)	63	2				
		<u>905</u> (53261)	44	2				
		<u>291</u> (53262)	95	2				
		<u>209</u> (53265)	61	2				
		<u>510</u> (53266)	73	2				
		<u>498</u> (53267)	35	2				
		<u>603</u> (53273)	62	2				
		<u>480</u> (71075)	32	1				
26		<u>2578</u> (54505)	125	10	Koning et al.	Dynamics of HIV Type 1 Recombination Following Superinfection.	firstsample	HIV-1
27		<u>170-baby</u> (1952)	11	1	Koulinska et al.	Hypermutation of HIV type 1	infection	HIV-1
		169-baby(3092)	16	1		genomes isolated from infants soon after vertical	seroconversion	
		210-baby(3108)	20	1		infection.		
28		<u>19</u> (50444)	60	1	Lewis et al.	Partial Escape of HIV-1 From	seroconversion	HIV-1
		<u>17</u> (50445)	85	1		Cytotoxic T Lymphocytes During Chronic Infection.		
29		<u>AD17</u> (45173)	246	1	<u>Li et al.</u>	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men	CHAVI infection seroconversion fiebig	HIV-1
30		<u>9012</u> (70515)	266	3	Lipscomb et al.	HIV Reverse Transcriptase	seroconversion	HIV-1
		<u>9017</u> (70516)	136	2		Drug Resistance Mutations	fiebig	
		<u>926</u> (70518)	315	3		during Early Infection Reveal Greater Transmission		
		<u>945</u> (70519)	374	3		Diversity than in Env.		
31	\checkmark	<u>0180</u> (27116)	37	18	Little et al.	Persistence of Transmitted	infection	HIV-1
		<u>0449</u> (27119)	34	17		Drug Resistance among		
		<u>0507</u> (27122)	21	12		Subjects with Primary Human Immunodeficiency		
		<u>0512</u> (27123)	19	19		<u>Virus Infection</u>		
		<u>0559</u> (27124)	11	11				
		<u>0575</u> (27125)	30	15				
		<u>0629</u> (27126)	21	12				
32		<u>PIC1362</u> (13654)	1185	17	<u>Liu et al.</u>	Selection on the human immunodeficiency virus type 1 proteome following	seroconversion	HIV-1

13					mira patient sequence sets		
22	DD(2/242/0)	47	4	1 to see al.	primary infection		1111/1/4
33	<u>PP63</u> (34368)	46	1	<u>Liu et al.</u>	Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to	seroconversion	HIV-1
	<u>LSC63</u> (34369)	96	1		prevent HIV type 1 infection from strains genetically unrelated to viruses in long- term exposed partners		
34	<u>patient 2</u> (1011)	231	12	<u>Lukashov et al.</u>	Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs	seroconversion firstsample	HIV-1
35	<u>62</u> (20451)	17	4	Lwembe et al.	Anti-retroviral drug	seroconversion	HIV-1
	<u>70</u> (20453)	17	3		resistance-associated mutations among non-		
	<u>85</u> (20455)	18	2		<u>subtype B HIV-1-infected</u> <u>Kenyan children with</u>		
	<u>83</u> (20670)	23	4		treatment failure		
36	<u>A</u> (44623)	43	2	Martinez et al.	Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia	starttreatment	HIV-1
37	<u>A</u> (44041)	49	1	Pacold et al.	Comparison of methods to	seroconversion	HIV-1
	<u>E</u> (44042)	49	1		detect HIV dual infection.		
	<u>B</u> (44043) <u>C</u> (44045)	50 54	1				
	<u>C</u> (44046)	91	2				
	<u>J</u> (44047)	46	1				
	<u>G</u> (44048)	53	1				
38	<u>A</u> (13205)	30	1	Parera et al.	Lack of Evidence for	seroconversion	HIV-1
	<u>B</u> (13206)	23	1		Protease Evolution in HIV-1- Infected Patients after 2		
	<u>C</u> (13207)	36	1		Years of Successful Highly		
	<u>E</u> (13209)	20	1		Active Antiretroviral Therapy		
	<u>F</u> (13210)	23	1				
	<u>G</u> (13211)	33	1				
	<u>H</u> (13212)	26	1				
	<u>J</u> (13213)	23	1				

	<u>I</u> (15790)	25	1				
39	<u>patient</u> (15816)	170	6	Pernas et al.	A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection	seroconversion firstsample	HIV-1
40	<u>6</u> (19980)	42	4	Persaud et al.	Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor- Resistant HIV-1 among Recently Infected Infants Born in the United States	PACTG P1030 seroconversion	HIV-1
41	<u>WC10</u> (3692)	20	1	Philpott et al.	Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination	seroconversion	HIV-1
42	NYU124(27799) NYU107(27800) NYU6518(27801) NYU129(27820)	245281175333	4 6 5 8	Powell et al.	Longitudinal quasispecies analysis of viral variants in HIV type 1 dually infected individuals highlights the importance of sequence identity in viral recombination.	firstsample	HIV-1
43	ESP1(2622) ESP2(2623) ESP3(2624)	43 55 18	4	<u>Quinones-</u> <u>Mateu et al.</u>	Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1	seroconversion	HIV-1
44	<u>P3</u> (40911) <u>P2</u> (40912) <u>P1</u> (40913)	122	9 <u>R</u> 5 7	lachinger et al.	Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission.	seroconversion firstsample	HIV-1
45	AA080(52202) AA044(52203) AA084(52204) AA057(52207) AA103(52209)	22 20 10 20 21	1 1 1 1	Rolland et al.	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.	RV144 seroconversion	HIV-1

<u>AA037</u> (52210)	10	1
<u>AA100</u> (52216)	23	1
<u>AA023</u> (52219)	22	1
<u>AA012</u> (52223)	22	1
<u>AA007</u> (52225)	11	1
<u>AA091</u> (52230)	21	1
<u>AA085</u> (52231)	10	1
<u>AA078</u> (52232)	20	1
<u>AA067</u> (52234)	11	1
<u>AA003</u> (52236)	25	1
<u>AA083</u> (52240)	21	1
<u>AA094</u> (52243)	27	1
<u>AA075</u> (52244)	10	1
<u>AA041</u> (52245)	21	1
<u>AA123</u> (52248)	18	1
<u>AA042</u> (52249)	23	1
<u>AA125</u> (52252)	19	1
<u>AA024</u> (52253)	10	1
<u>AA001</u> (52256)	21	1
<u>AA104</u> (52257)	23	1
<u>AA096</u> (52259)	10	1
<u>AA019</u> (52260)	11	1
<u>AA090</u> (52261)	10	1
<u>AA033</u> (52262)	10	1
<u>AA014</u> (52263)	16	1
AA029(52264)	20	1
<u>AA006</u> (52265)	19	1
<u>AA065</u> (52266)	23	1
<u>AA016</u> (52267)	20	1
<u>AA030</u> (52271)	10	1
<u>AA004</u> (52273)	10	1
<u>AA117</u> (52274)	25	1
<u>AA098</u> (52275)	20	1
<u>AA040</u> (52277)	10	1
<u>AA059</u> (52278)	10	1
<u>AA121</u> (52286)	23	1

46

47

			mira patient sequence sets		
<u>AA088</u> (52287)	12	1			
<u>AA118</u> (52291)	21	1			
<u>AA082</u> (52292)	10	1			
<u>AA068</u> (52293)	10	1			
<u>AA072</u> (52295)	10	1			
AA025(52296)	10	1			
<u>AA101</u> (52297)	22	1			
<u>AA116</u> (52299)	23	1			
AA048(52300)	25	1			
AA061(52302)	20	1			
<u>AA027</u> (52303)	10	1			
<u>AA010</u> (52306)	12	1			
<u>AA113</u> (52307)	20	1			
<u>AA011</u> (52309)	19	1			
<u>AA092</u> (52310)	28	1			
<u>AA086</u> (52311)	21	1			
<u>AA021</u> (52312)	22	1			
<u>AA049</u> (52313)	17	1			
<u>AA105</u> (52314)	20	1			
<u>AA093</u> (52316)	15	1			
<u>AA060</u> (52318)	10	1			
<u>AA111</u> (52319)	11	1			
<u>AA081</u> (52320)	22	1			
<u>AA097</u> (52321)	21	1			
<u>QC168</u> (1117)	42	3 <u>Sagar et al.</u>	<u>Diversity in HIV-1 Envelope</u>	infection	HIV-1
<u>QA284</u> (3951)	41	3	V1-V3 Sequences Early in Infection Reflects Sequence		
<u>Q03</u> (3955)	46	3	Diversity Throughout the		
<u>QA779</u> (5553)	48	2	HIV-1 Genome But Does Not		
<u>QB424</u> (5556)	61	3	Predict the Extent of		
QC890(5557)	54	3	Sequence Diversity During Chronic Infection		
<u>QB596</u> (5559)	63	3	<u>emone infection</u>		
<u>QB670</u> (5560)	35	2			
<u>B-child</u> (13592)	202	Sundaravaradan	Conservation of functional	seroconversion	HIV-1
<u>B-mother</u> (3041)	189	<u>et al.</u>	domains and limited heterogeneity of HIV-1		
<u>C-mother</u> (3042)	142		reverse transcriptase gene		
<u>F-mother</u> (3045)	177		following vertical		

		<u>H-mother</u> (3046)	57	1	transmission.		
		<u>D-mother</u> (3049)	184				
48		<u>\$1</u> (1651)	130	9 <u>Tobin et al.</u>	Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.	seroconversion firstsample	HIV-1
49		<u>MM50</u> (36110)	224	3 Turnbull et al.	Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection	Mortimer seroconversion Market Centre	HIV-1
50	✓	<u>2</u> (28761)		3 <u>van Marle et al.</u>	resistant HIV in the colon compared to blood and other	firstsample	HIV-1
		<u>42</u> (28762)	103	1	<u>gastrointestinal</u> <u>compartments in HIV</u> <u>infection.</u>		
51		<u>2</u> (28761)	105	3 <u>van Marle et al.</u>	Compartmentalization of the	firstsample	HIV-1
		<u>42</u> (28762)	103	1	gut viral reservoir in HIV-1 infected patients		
				Retrieve se	elected sets Reset		

last modified: Wed May 30 15:32 2012

Questions or comments? Contact us at seq-info@lanl.gov.